- Healthcare Professionals
- Research
- Clinical trials
- mk3543-006
Haematology
Haematology
2024-12-01T00:00:00.000+00:00
MK3543-006
MK3543-006
Haematology
A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea.
A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea.
Trial overview
Description
A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea.
Study details
For detailed information on this trial, please click here
Trial status
Due to open January 2025
Location
Windsor
:::
Principal Investigator
Dr Pratap Neelakatan